Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis.

Dietze, Reynaldo; Fowler, Vance G.; Steiner, Theodore S.; Peçanha, Paulo Mendes; Corey, G. Ralph

doi:10.4269/ajtmh.1999.60.837

Cited by 22 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a report of four patients with the acute form treated with amphotericin B colloidal dispersion, three had complete response and one responded partially after 28 days of treatment. All three complete responders relapsed after 2, 3, or 6 months [48]. These data support the concept that patients treated with amphotericin B still need to complete a longer period of treatment with an azole or sulfonamide to prevent relapse.…”

Section: Diagnosissupporting

confidence: 72%

Paracoccidioidomycosis

Nucci

Colombo²,

Queiroz‐Telles³

2009

Curr Fungal Infect Rep

View full text Add to dashboard Cite

Section: Diagnosissupporting

confidence: 72%

Paracoccidioidomycosis

Nucci

Colombo²,

Queiroz‐Telles³

2009

Curr Fungal Infect Rep

View full text Add to dashboard Cite

“…On the basis of the results of this study, voriconazole (also available in an intravenous formulation) should be evaluated as an alternative to amphotericin B for the initial treatment of severe paracoccidioidomycosis, especially considering the relapse rate [2] and the toxicity associated with amphotericin B deoxycholate. Although lipidbased formulations have better tolerability than does conventional amphotericin B, they have been associated with treatment failures for paracoccidioidomycosis [22].…”

Section: Discussionmentioning

confidence: 99%

An Open-Label Comparative Pilot Study of Oral Voriconazole and Itraconazole for Long-Term Treatment of Paracoccidioidomycosis

Telles

Goldani

Schlamm

et al. 2007

Clinical Infectious Diseases

100

View full text Add to dashboard Cite

Background. In previous studies, itraconazole was revealed to be an effective therapy and was considered to be the gold standard treatment for mild-to-moderate acute and chronic clinical forms of paracoccidioidomycosis. A pilot study was conducted to investigate the efficacy, safety, and tolerability of voriconazole for the long-term treatment of acute or chronic paracoccidioidomycosis, with itraconazole as the control treatment. Methods.A randomized, open-label study was conducted at 3 Brazilian tertiary care hospitals. Patients were randomized (at a 2:1 ratio) to receive oral therapy with voriconazole or itraconazole for 6 months. Patients receiving у1 dose of study drug were evaluated for safety; patients with confirmed paracoccidioidomycosis who completed у6 months of therapy (treatmentevaluable patients) were evaluated for treatment efficacy. Satisfactory global response was assessed at the end of treatment.Results. Fifty-three patients were evaluated for treatment safety (35 received voriconazole, and 18 received itraconazole). Both drugs were well tolerated. The most common treatment-related adverse events in the voriconazole group included abnormal vision, chromatopsia, rash, and headache; the most common treatment-related adverse events in the itraconazole group included bradycardia, diarrhea, and headache. Liver function test values were slightly higher in patients receiving voriconazole than in those receiving itraconazole; 2 patients in the voriconazole group were withdrawn from treatment because of increased liver function test values. In the intent-to-treat populations, the satisfactory response rate (i.e., complete or partial global response) was 88.6% among the voriconazole group and 94.4% among the itraconazole group. The response rate among treatment-evaluable patients was 100% for both treatment groups; no relapses were observed after 8 weeks of follow-up.Conclusions. This is, to our knowledge, the first study to demonstrate that voriconazole is as well tolerated and effective as itraconazole for the long-term treatment of paracoccidioidomycosis.

show abstract

“…The lipid based agents which are most easily readily available for clinical use are Amphotericin B lipid complex and Liposomal Amphotericin B 113,114 . A 3rd lipid based merchandise amphotericin B colloidal dispersion is correlated with more temperature and chills compared with traditional amphotericin 115 . The primary purpose for voriconazole is in the therapy of invasive aspergillosis, where it is become the favoured therapy of invasive pulmonary aspergillus in older kids and adults 116 .…”

Section: Coccidioidomycosis Is Generally Caused Bymentioning

confidence: 99%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

Statistical figures represent that fungal infections are the major cause of thousands of deaths each year. Despite the availability of treatment options invasive and systemic fungal infections have alarmingly higher mortality rates. This current review tabulates such fungal organisms that are pathogenic and fatal to human. This article provides a compilation of all Mycoses in human and also reports about the risk group of each fungus based on which, the level of risk caused by fungi can be determined. Infections caused by Dimorphic fungal pathogens (Blastomyces, Coccidioides, Marneffei) and Dematiaceous hyphomycetes (Cladophialophora, Rhinocladiella) belong to major fatal causing risk group 3 resulting in higher death rates of individuals. It also reports about various types of possible classification of mycoses i.e. based on reaction of human to fungi, host susceptibility, pathogen type, body location and risk group. The article highlights the estimated incidence of fungal diseases due to these pathogens, but these statistical figures are usually underestimated so there is a great need for advancement in understanding of fungus, their resistance along with immunity reports. In order to meet all these disease combating requirements, many high quality research initiatives with proper sources of funding and encouragement have to be provided. Article also reviews the major antifungal drugs available along with their brief pharmacokinetic profile. It also briefs some take home remedies in order to prevent and treat major fungal infection along with the alternative and novel modelling techniques developed recently for drug designing to target various development stages of fungal organism.

show abstract

Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis.

Cited by 22 publications

References 15 publications

Paracoccidioidomycosis

Paracoccidioidomycosis

An Open-Label Comparative Pilot Study of Oral Voriconazole and Itraconazole for Long-Term Treatment of Paracoccidioidomycosis

Untitled

Contact Info

Product

Resources

About